Payment overview · 2025
General Payments
$665.65
34 reported records · 13 companies
Healthcare provider profile · identity verified
Jerome Lee Sang, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PORTLAND, TX · NPI 1164449948
Verified facts
What the public records show
CMS Open Payments records show Jerome Lee Sang, MD received $665.65 in general payments during 2025 across 34 reported records.
Lilly USA, LLC accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 540 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $123.41 | 18.5% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $110.20 | 16.6% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $102.87 | 15.4% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $73.72 | 11.1% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $54.31 | 8.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $40.09 | 6.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.94 | 5.7% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.96 | 3.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.93 | 3.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.56 | 3.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.68 | 2.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.67 | 2.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.31 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $665.65 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $110.20 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $102.87 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $97.71 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $97.71 | 5 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $56.66 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $54.31 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $40.09 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.93 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $10.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 87 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 76 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 26 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 540 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 100 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 87 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
87 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
87 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
540 | 98 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
49 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
100 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1042 | 244 |
| Amlodipine Besylate | Amlodipine Besylate | 935 | 225 |
| Atorvastatin Calcium | Atorvastatin Calcium | 923 | 252 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 877 | 200 |
| Metoprolol Succinate | Metoprolol Succinate | 824 | 202 |
| Gabapentin | Gabapentin | 696 | 175 |
| Pantoprazole Sodium | Pantoprazole Sodium | 579 | 151 |
| Furosemide | Furosemide | 576 | 147 |
| Losartan Potassium | Losartan Potassium | 576 | 159 |
| Mounjaro | Tirzepatide | 540 | 98 |
| Potassium Chloride | Potassium Chloride | 506 | 121 |
| Lisinopril | Lisinopril | 504 | 134 |
| Tamsulosin Hcl | Tamsulosin Hcl | 445 | 98 |
| Prednisone | Prednisone | 360 | 253 |
| Alprazolam | Alprazolam | 348 | 82 |
| Tramadol Hcl | Tramadol Hcl | 342 | 103 |
| Duloxetine Hcl | Duloxetine Hcl | 331 | 75 |
| Simvastatin | Simvastatin | 324 | 85 |
| Azithromycin | Azithromycin | 297 | 226 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 292 | 95 |
| Trazodone Hcl | Trazodone Hcl | 269 | 62 |
| Clopidogrel | Clopidogrel Bisulfate | 256 | 53 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 249 | 69 |
| Fluoxetine Hcl | Fluoxetine Hcl | 248 | 57 |
| Donepezil Hcl | Donepezil Hcl | 245 | 44 |
| Metformin Hcl | Metformin Hcl | 244 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 240 | 114 |
| Omeprazole | Omeprazole | 233 | 68 |
| Montelukast Sodium | Montelukast Sodium | 230 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 229 | 48 |
| Eliquis | Apixaban | 217 | 48 |
| Baclofen | Baclofen | 216 | 70 |
| Escitalopram Oxalate | Escitalopram Oxalate | 195 | 40 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 189 | 138 |
| Allopurinol | Allopurinol | 183 | 39 |
| Famotidine | Famotidine | 179 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 173 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 50 |
| Doxepin Hcl | Doxepin Hcl | 163 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 162 | 38 |
| Lorazepam | Lorazepam | 156 | 48 |
| Clonazepam | Clonazepam | 154 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 148 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 145 | 26 |
| Carvedilol | Carvedilol | 144 | 37 |
| Glimepiride | Glimepiride | 142 | 37 |
| Divalproex Sodium | Divalproex Sodium | 139 | 24 |
| Pregabalin | Pregabalin | 139 | 33 |
| Sertraline Hcl | Sertraline Hcl | 138 | 28 |
| Clonidine Hcl | Clonidine Hcl | 133 | 48 |
| Mirtazapine | Mirtazapine | 130 | 29 |
| Cefdinir | Cefdinir | 107 | 87 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | 16 |
| Memantine Hcl | Memantine Hcl | 106 | 23 |
| Metformin Hcl Er | Metformin Hcl | 103 | 33 |
| Myrbetriq | Mirabegron | 102 | 19 |
| Ozempic | Semaglutide | 100 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 97 | 29 |
| Spironolactone | Spironolactone | 96 | 25 |
| Buspirone Hcl | Buspirone Hcl | 92 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 20 |
| Finasteride | Finasteride | 88 | 15 |
| Nystatin | Nystatin | 88 | 50 |
| Farxiga | Dapagliflozin Propanediol | 87 | 18 |
| Levetiracetam | Levetiracetam | 87 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 87 | 15 |
| Estradiol | Estradiol | 85 | 22 |
| Xarelto | Rivaroxaban | 85 | 18 |
| Meloxicam | Meloxicam | 84 | 24 |
| Aripiprazole | Aripiprazole | 83 | 17 |
| Latanoprost | Latanoprost | 81 | 12 |
| Methocarbamol | Methocarbamol | 78 | 35 |
| Jardiance | Empagliflozin | 76 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 75 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 72 | 16 |
| Fentanyl | Fentanyl | 71 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 70 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 69 | 58 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 67 | 11 |
| Glipizide | Glipizide | 64 | 18 |
| Alendronate Sodium | Alendronate Sodium | 63 | 21 |
| Topiramate | Topiramate | 62 | 15 |
| Warfarin Sodium | Warfarin Sodium | 62 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 61 | 15 |
| Ondansetron Odt | Ondansetron | 59 | 40 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 55 | 11 |
| Atenolol | Atenolol | 54 | 15 |
| Irbesartan | Irbesartan | 54 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 54 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 33 |
| Ezetimibe | Ezetimibe | 52 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 49 | 16 |
| Fluconazole | Fluconazole | 49 | 35 |
| Promethazine Hcl | Promethazine Hcl | 49 | 20 |
| Trulicity | Dulaglutide | 49 | 13 |
| Bupropion Xl | Bupropion Hcl | 48 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 27 |
| Entresto | Sacubitril/Valsartan | 47 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 47 | 20 |
| Tresiba Flextouch U-200 | Insulin Degludec | 46 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 24 |
| Valsartan | Valsartan | 45 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 28 |
| Celecoxib | Celecoxib | 44 | 16 |
| Morphine Sulfate Er | Morphine Sulfate | 44 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 14 |
| Bumetanide | Bumetanide | 43 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 13 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 43 | 21 |
| Sumatriptan Succinate | Sumatriptan Succinate | 43 | 11 |
| Temazepam | Temazepam | 43 | 15 |
| Diazepam | Diazepam | 42 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 36 |
| Clindamycin Hcl | Clindamycin Hcl | 41 | 23 |
| Lovastatin | Lovastatin | 41 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | 11 |
| Sucralfate | Sucralfate | 41 | 14 |
| Fenofibrate | Fenofibrate | 40 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 37 | 37 |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Methadone Hcl | Methadone Hcl | 35 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Primidone | Primidone | 33 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 32 | suppressed |
| Lactulose | Lactulose | 32 | 12 |
| Azelastine Hcl | Azelastine Hcl | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Novolog Flexpen | Insulin Aspart | 31 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 31 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 30 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 25 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 29 | 23 |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Gemtesa | Vibegron | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 14 |
| Colchicine | Colchicine | 27 | 11 |
| Digoxin | Digoxin | 27 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 27 | suppressed |
| Ranolazine Er | Ranolazine | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 21 |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Linzess | Linaclotide | 26 | 12 |
| Constulose | Lactulose | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 25 | 22 |
| Tradjenta | Linagliptin | 25 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 20 |
| Belsomra | Suvorexant | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 15 |
| Armour Thyroid | Thyroid,pork | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Jantoven | Warfarin Sodium | 21 | suppressed |
| Lubiprostone | Lubiprostone | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 20 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 19 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 19 | 12 |
| Olanzapine | Olanzapine | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | 11 |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | 12 |
| Nitroglycerin | Nitroglycerin | 18 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Enulose | Lactulose | 17 | suppressed |
| Leflunomide | Leflunomide | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Budesonide | Budesonide | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | 12 |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 13 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 12 | suppressed |
| Euthyrox | Levothyroxine Sodium | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Insulin Glargine Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Zocor | Simvastatin | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $665.65 · 34 records | Lilly USA, LLC | CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, IBSRELA, INSPIRE, JARDIANCE, KISUNLA, Kerendia, LINZESS, MOUNJARO, Ozempic, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error